The use of the cytotoxic T lymphocyte-associated antigen-4-immunoglobulin (CTLA4-Ig) fusion protein abatacept for costimulatory blockade of T lymphocytes holds promise as a potentially effective anti-neuroinflammatory treatment for RRMS. Here, CTLA4 is linked to relapsing-remitting multiple sclerosis.